Sivik Global Healthcare LLC Cuts Holdings in Johnson & Johnson (NYSE:JNJ)

Sivik Global Healthcare LLC lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 28.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the company’s stock after selling 10,000 shares during the period. Johnson & Johnson makes up about 2.5% of Sivik Global Healthcare LLC’s holdings, making the stock its 18th biggest holding. Sivik Global Healthcare LLC’s holdings in Johnson & Johnson were worth $4,438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Vanguard Group Inc. grew its stake in Johnson & Johnson by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after buying an additional 3,358,478 shares in the last quarter. GQG Partners LLC boosted its stake in shares of Johnson & Johnson by 64.4% in the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after purchasing an additional 2,547,378 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Johnson & Johnson by 37.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after purchasing an additional 1,805,632 shares in the last quarter. Swiss National Bank boosted its stake in shares of Johnson & Johnson by 14.0% in the 1st quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock valued at $2,020,868,000 after purchasing an additional 1,396,500 shares in the last quarter. Finally, Bridgewater Associates LP boosted its stake in shares of Johnson & Johnson by 40.3% in the 1st quarter. Bridgewater Associates LP now owns 4,345,002 shares of the company’s stock valued at $770,065,000 after purchasing an additional 1,247,260 shares in the last quarter. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Johnson & Johnson Stock Up 0.8 %

Shares of Johnson & Johnson stock opened at $176.20 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The company has a 50-day moving average of $167.84 and a 200 day moving average of $171.29. The firm has a market cap of $460.67 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business earned $2.60 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.57%. Johnson & Johnson’s payout ratio is 62.95%.

Johnson & Johnson announced that its Board of Directors has initiated a share repurchase plan on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Raymond James cut their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a report on Thursday. They set a “neutral” rating and a $170.00 price target for the company. Citigroup lowered their price target on shares of Johnson & Johnson from $201.00 to $198.00 in a report on Wednesday, October 5th. Barclays assumed coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target for the company. Finally, StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $181.33.

Insider Activity at Johnson & Johnson

In related news, insider William Hait sold 15,000 shares of the stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Peter Fasolo sold 22,864 shares of the stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the sale, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Hait sold 15,000 shares of the stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now directly owns 80,236 shares in the company, valued at $13,764,485.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 118,795 shares of company stock valued at $20,230,174. 0.35% of the stock is owned by insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.